frequency compared to placebo, but are expensive and commonly cause constipation and nausea as well. 6 In a complex and likely multifactorial disease like IBS, a multimodal approach is necessary as each agent tends to target individual symptoms, for example abdominal bloating or pain, diarrhoea or constipation. 7, 8 Furthermore, cost concerns exist as repeated courses of treatment are required as IBS is often a chronic, relapsing condition. 9 Melatonin, N-acetyl-5-methoxytryptamine, is a hormone produced naturally by the pineal gland in humans, as well as the enterochromaffin cells of the gastrointestinal mucosa. 10 The concentration of melatonin in the digestive mucosa typically exceeds that found in the blood, by up to 100 times. 11 In most countries, including the United States of America (USA), melatonin is easily available as an over-the-counter oral supplement. 12 Besides its sleep and circadian rhythm regulatory effects, current research has reported the modulatory effects of melatonin on pain, local inflammation and motility in the gastrointestinal tract, which could be of particular benefit to sufferers of IBS. 13 Furthermore, it has been shown that IBS sufferers have significantly lower baseline saliva melatonin levels 14 and lower 6-sulphatoxymelatonin (6-SMLT)/creatinine level 15 than healthy controls. Exogenous melatonin supplementation has also been shown to be able to improve saliva melatonin levels. 14 However, due to extensive first-pass metabolism by the liver, the physiological effects of melatonin are limited by its short half-life of 30-50 minutes. 16 Agomelatine, a naphthalene analog of melatonin (see Figure 1) , is a novel melatonergic drug with a longer half-life (approximately 2.3 hours) and a comparatively greater affinity for MT1 and MT2 melatonin receptors than melatonin itself. 17 Agomelatine is currently licensed for use in major depressive disorder. 18 We believe that agomelatine is a hitherto unexplored therapeutic option for the management of IBS. Apart from the fact that IBS is commonly associated with anxiety and depression, 19 agomelatine could help alleviate the somatic symptoms (abdominal discomfort or pain and diarrhoea) of IBS through its action at the MT1 and MT2 melatonin receptors and serotonin 5-HT3 receptor antagonist activity.
| COMMENT
As only one clinical trial involving valdoxan ® (brand of medicine containing the active ingredient agomelatine) exists, 20 a meta-analysis approach was not possible. The available clinical trials involving the use of agomelatine and/or exogenous melatonin in patients with IBS are summarized in Table 1 . 
29,30
Third, melatonin is thought to have antinociceptive effects, modulating pain sensation and pain threshold. A number of studies involving acute and inflammatory pain animal models have demonstrated the antinociceptive effects of melatonin. 31 MT1/MT2 melatonergic receptors are found in the spinal cord, and the underlying mechanism probably involves opioid, benzodiazepine, α1-and α2-adrenergic, serotonergic and cholinergic receptors. 32 Melatonin has also been found to potentiate the analgesic effects of δ-opioid receptor agonists. 33 Last but not least, melatonin improves sleep quality, which could be related to the severity of IBS symptoms. 34, 35 Rapid eye movement (REM) sleep disorders are highly comorbid with IBS. 36 It is hypothesized that sleep disorders in patients with IBS are a result of increased kynurenine pathway (a tryptophanmetabolite) activity, with a consequent decrease in the serotonin/melatonin pathway. 37, 38 Moreover, improvements in sleep quality have been shown to improve IBS symptoms. 39 Besides the added advantage of a longer duration of action of agomelatine compared to melatonin, agomelatine also has demonstrated antidepressant activity. 40 Anxiety and depression are highly comorbid with IBS, 19 and psychosocial factors (eg, mood and stress)
are correlated with IBS disease severity and pain sensation. 41 Antidepressants have proven efficacy for the management of IBS. Based on studies on the use of agomelatine for depressive disorders, the usual starting dose is 25 mg/d at bedtime, uptitrated to a maximum dose of 50 mg/d. 44 Side effects are generally uncommon, but agomelatine may be hepatotoxic and cause dizziness. 45 
| WHAT IS NE W AND CON CLUS I ON
Agomelatine is a potentially useful addition to our armamentarium 
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D I SCL A I M ER
Agomelatine is currently not labelled for the use under discussion.
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